Skip to content

The Effect of Home-based Exercise on Functional Capacity of Covid-19 Survivor With Cardiovascular Comorbidity

The Effect of Home-based Breathing and Chest Mobilisation Exercise on Cardiorespiratory Functional Capacity of Covid-19 Survivor With Cardiovascular Comorbidity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05077943
Enrollment
46
Registered
2021-10-14
Start date
2021-09-01
Completion date
2023-02-20
Last updated
2023-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breathing Exercise, Cardiovascular Diseases, Covid19

Brief summary

Objective propose: to investigate the effect of home based breathing exercise and chest mobilization on the cardiorespiratory functional capacity of Covid-19 survivors with cardiovascular comorbidity. Breathing exercise and chest mobilization are proven to increase lung functional capacity in Covid-19 survivors. It is hypothesized that breathing exercise and chest mobilization in Covid-19 survivors will give benefits to Covid-19 survivors with cardiovascular disease.

Detailed description

Lung restrictive disorder is one of the reasons that induce chronic fatigue in COVID-19 (Corona Virus Disease-19) survivors. It also gives a significant effect on cardiovascular patients who are in the second phase of cardiac rehabilitation. Breathing exercise and chest mobilization are proven to increase lung functional capacity in Covid-19 survivors. On the other hand, there is still no research that shows the effectiveness of Breathing exercises and chest mobilization in Covid-19 survivors who are suffering from cardiovascular problems. Patients in National Cardiac Center Hospital, Jakarta, with a history of Covid-19 and have cardiovascular disease are recruited. They will undergo pre and post-exercise examinations such as blood sampling, do 6 minutes walking test, Peak Cough Flow and Peak Flow Rate test, measuring the chest dimension, treadmill, and answer the European Quality of Life Five Dimension (EQ-5D) questions. With randomization, patients will be determined to treatment or control group. They will be prepared about what exercises should they do at home. Subjects will be supervised digitally and regularly through Zoom meetings. Exercises will be done for 3 months.

Interventions

BEHAVIORALBreathing and chest mobilization exercises

Patients walk regularly 5 times per week and increase the distance day by day according to their improved ability. Patients also do breathing and chest mobilization exercise 3 times per week. It is a recorded moderated exercise for 30 minutes duration. Patients can access the video as a home-based activity through an online videos platform and will be supervised.

BEHAVIORALSecond phase cardiac rehabilitation

Independently, patients walk regularly 5 times per week and increase the distance day by day according to their improved ability without breathing and chest mobilization exercise.

Sponsors

National Cardiovascular Center Harapan Kita Hospital Indonesia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients who got infected by Covid-19 in 3 months before recruitment and suffering cardiovascular disease * Able to communicate and operate Youtube and Zoom.

Exclusion criteria

* Limitation to move any part of the body that causes the inability to do the instructed exercise. * Feel pain in extremities (visual analog scale \>3) * Chronic Obstructive Pulmonary Disease * Neuromuscular disorder (stroke, peripheral neuropathy with significant motoric control disturbance * Musculoskeletal disorder (fracture, post amputation, severe arthritis in support joints)

Design outcomes

Primary

MeasureTime frameDescription
Change of Peak Cough Flow (PC)Change from Baseline Peak Cough Flow (PC) at 3 monthsto define the functional capacity. Unit of measure : L/min.
Change of Peak Flow Rate (PFR)Change from Baseline Peak Flow Rate (PFR) at 3 monthsto define the functional capacity. Unit of measure : L/min.
Change of Cardiac Exercise TestChange from Baseline Cardiac Exercise Test at 3 monthsPatients walk on treadmill. Unit of measure : minutes, METs (Metabolic Equivalent of Task)
Change of 6-minutes walking testChange from Baseline 6-minutes walking test at 3 monthsTo define initial ability to walk in 30 minutes for second phase cardiac rehabilitation (aerobic exercise). Unit of measure : meter

Secondary

MeasureTime frameDescription
Change of Mean Corpuscular HemoglobinChange from Baseline Mean Corpuscular Hemoglobin at 3 monthsMean Corpuscular Hemoglobin (pg)
Change of Mean Corpuscular Hemoglobin ConcentrationChange from Baseline Mean Corpuscular Hemoglobin Concentration at 3 monthsMean Corpuscular Hemoglobin Concentration (%)
Change of Red Cell Distribution WidthChange from Baseline Red Cell Distribution Width at 3 monthsRed Cell Distribution Width (%)
Change of LeucocyteChange from Baseline Leucocyte at 3 monthsLeucocyte (/µL)
Change of PlateletChange from Baseline Platelet at 3 monthsPlatelet (thousand/µL)
Change of European Quality of Life Five Dimension (EQ-5D)Change from Baseline EQ-5D at 3 months1=have no problem, 2=have slight problem, 3=moderate problem, 4=severe problem, 5=unable to do. We will compare the points between pre and post exercise and looking the improvement.
Change of HemoglobinChange from Baseline Hemoglobin at 3 monthsHemoglobin (g/dL)
Change of EosinophilChange from Baseline Eosinophil at 3 monthsEosinophil (/µL)
Change of NeutrophilChange from Baseline Neutrophil at 3 monthsNeutrophil (/µL)
Change of LymphocyteChange from Baseline Lymphocyte at 3 monthsLymphocyte (/µL)
Change of MonocyteChange from Baseline Monocyte at 3 monthsMonocyte (/µL)
Change of C-Reactive ProteinChange from Baseline C-Reactive Protein at 3 monthsto determine infection markers. Unit of measure : mg/L
Change of D-dimerChange from Baseline D-dimer at 3 monthsUnit of measure : ng/mL
Change of BasophilChange from Baseline Basophil at 3 monthsBasophil (/µL)
Change of HematocritChange from Baseline Hematocrit at 3 monthsHematocrit (%)
Change of ErythrocyteChange from Baseline Erythrocyte at 3 monthsErythrocyte (million/µL)
Change of Mean Corpuscular VolumeChange from Baseline Mean Corpuscular Volume at 3 monthsMean Corpuscular Volume (fL)

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026